One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Iovance Biotherapeutics logo
Iovance Biotherapeutics IOVA
$ 6.9 -5.61%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Iovance Biotherapeutics Balance Sheet 2025-2007 | IOVA

Brief overview of Iovance Biotherapeutics's balance sheet strength

This overview follows the five latest available annual observations between 2021 and 2025.

Assets added +17.5%, reaching $913.2 million from $777.3 million five periods earlier; annual growth near 4.1% remained solid.

Liabilities expanded faster than the asset base, +37.8% versus +17.5%. Debt-service capacity deserves attention.

Equity accounts for 76.5% of assets. Against the initial 80%, the capital position looks resilient.

Negative net debt of -$114.6 million means cash holdings are larger than debt obligations.

Cash equals 17.9% of the balance sheet, compared with 10.1% five periods ago. This is the readily available cushion.

Retained earnings are negative at -$2.8 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Overall assessment

Taken together, the figures indicate acceptable resilience for Iovance Biotherapeutics. The next assessment depends on debt and equity trends.

Annual Balance Sheet Iovance Biotherapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Net Debt

-115 M -58.4 M -40 M -147 M -7.7 M -15.7 M -2.47 M -82.2 M -145 M -107 M -13.6 M -44.9 M -19.7 M 6.48 M 4.49 M - - - -

Long Term Debt

44.4 M 44.4 M 67.1 M 71.9 M 65.5 M 45.4 M - - - - - - - - - - - - -

Long Term Debt Current

4.04 M 12.9 M 7.78 M 12.6 M 5.06 M 6.28 M 7.25 M - - - - - - - - - - - -

Total Non Current Liabilities

76.2 M 77.7 M 85.4 M 72.9 M 66.5 M 57.1 M 6.6 M 230 K 297 K - - - - - - - - - -

Total Current Liabilities

138 M 122 M 110 M 91.5 M 89.2 M 54.9 M 39.1 M 14.4 M 9.6 M 4.97 M 1.63 M 1.66 M 2.27 M 11.3 M 13.3 M 823 K - - -

Total Liabilities

215 M 200 M 196 M 164 M 156 M 112 M 45.7 M 14.6 M 9.89 M 4.97 M 1.63 M 1.66 M 2.27 M 11.3 M 13.3 M - - - -

Retained Earnings

-2.78 B -2.38 B -2.01 B -1.57 B -1.17 B -830 M -571 M -373 M -249 M -157 M -104 M -76.6 M -64.5 M -30.7 M -27.4 M -1.68 M - - -

Total Assets

913 M 910 M 780 M 664 M 777 M 768 M 345 M 481 M 155 M 172 M 106 M 46.5 M 19.9 M 29.4 K 568 K 1.46 M - - -

Cash and Cash Equivalents

163 M 116 M 115 M 232 M 78.2 M 67.3 M 14 M 82.2 M 145 M 107 M 33.6 M 44.9 M 19.7 M - 510 K 1.29 M 8.26 K 2.9 K -

Book Value

699 M 710 M 585 M 500 M 622 M 656 M 299 M 466 M 145 M 167 M 104 M 44.8 M 17.6 M -11.3 M -12.8 M 1.46 M - - -

Total Shareholders Equity

699 M 710 M 585 M 500 M 622 M 656 M 299 M 466 M 145 M 167 M 104 M 44.8 M 17.6 M -11.3 M -12.8 M 638 K -13.5 K 2.28 K 8 K

All numbers in USD currency

Quarterly Balance Sheet Iovance Biotherapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

42.8 M 43.3 M 43.9 M 44.4 M 45.2 M 45.1 M 44.2 M 44.4 M 66.4 M 69.2 M 72.3 M 67.1 M 68 M 68.8 M 69.6 M 71.9 M 71.9 M - 71.2 M 65.5 M 64.7 M 46.8 M 47.1 M 45.4 M 45.4 M 45.4 M 45.4 M 4.25 M 4.25 M 4.25 M 4.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

72.8 M 72.6 M 74.5 M 76.2 M 76.9 M 79.8 M 76.2 M 77.7 M 99.6 M 102 M 107 M 85.4 M 87.4 M 90.1 M 70.6 M 72.9 M 72.9 M - 72.2 M 66.5 M 65.7 M 47.8 M 48.1 M 57.1 M 57.1 M 57.1 M 57.1 M 6.6 M 6.6 M 6.6 M 4.43 M 230 K 230 K 230 K 230 K 297 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

179 M 179 M 204 M 215 M 203 M 209 M 199 M 200 M 218 M 196 M 190 M 196 M 178 M 179 M 158 M 164 M 152 M - 149 M 156 M 130 M 108 M 103 M 112 M 112 M 112 M 112 M 45.7 M 45.7 M 45.7 M 26.6 M 14.6 M 14.6 M 14.6 M 14.6 M 9.89 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-2.92 B -2.9 B -2.85 B -2.78 B -2.7 B -2.61 B -2.5 B -2.38 B -2.31 B -2.22 B -2.13 B -2.01 B -1.9 B -1.78 B -1.68 B -1.57 B -1.46 B - -1.26 B -1.17 B -1.07 B -987 M -906 M -830 M -830 M -830 M -830 M -571 M -571 M -571 M -410 M -373 M -340 M -306 M -276 M -249 M -223 M -201 M -178 M -157 M -141 M -123 M -111 M -104 M -95.8 M -88.2 M -81.9 M -76.6 M -71.7 M -68.9 M -66.8 M -64.5 M -64.5 M -64.5 M -64.5 M -30.7 M -30.7 M -30.7 M -30.7 M -27.4 M -27.4 M -27.4 M -27.4 M

Total Assets

991 M 916 M 926 M 913 M 905 M 907 M 967 M 910 M 991 M 964 M 870 M 780 M 852 M 757 M 825 M 664 M 546 M - 701 M 777 M 829 M 853 M 751 M 768 M 768 M 768 M 768 M 345 M 345 M 345 M 462 M 481 M 271 M 285 M 307 M 155 M 174 M 138 M 155 M 172 M 182 M 194 M 101 M 106 M 112 M 115 M 114 M 46.5 M 17.4 M 18.5 M 18.1 M 19.9 M 19.9 M 19.9 M 19.9 M 29.4 K 29.4 K 29.4 K 29.4 K 568 K 568 K 568 K 568 K

Cash and Cash Equivalents

64 M 117 M 202 M 169 M 164 M 138 M 178 M 122 M 171 M 235 M 141 M 181 M 334 M 296 M 543 M 232 M 118 M 108 M 92.4 M 84.3 M 58.6 M 82.8 M 132 M 72.9 M 67.3 M 67.3 M 67.3 M 19.4 M 14 M 14 M 54.1 M 82.2 M 80.7 M 246 M 297 M 145 M 163 M 114 M 107 M 107 M 92.9 M 121 M 38.9 M 33.6 M 30.8 M 12.6 M 111 M 44.9 M 17.2 M 18.4 M 17.9 M 19.7 M 19.7 M 19.7 M 19.7 M 510 K - 15.5 K - 510 K 510 K 510 K 510 K

Book Value

813 M 736 M 722 M 699 M 702 M 698 M 768 M 710 M 773 M 769 M 680 M 585 M 674 M 579 M 667 M 500 M 394 M - 552 M 622 M 698 M 744 M 647 M 656 M 656 M 656 M 656 M 299 M 299 M 299 M 435 M 466 M 256 M 270 M 293 M 145 M 174 M 138 M 155 M 172 M 182 M 194 M 101 M 106 M 112 M 115 M 114 M 46.5 M 17.4 M 18.5 M 18.1 M 19.9 M 19.9 M 19.9 M 19.9 M 29.4 K 29.4 K 29.4 K 29.4 K 568 K 568 K 568 K 568 K

Total Shareholders Equity

813 M 736 M 722 M 699 M 702 M 698 M 768 M 710 M 773 M 769 M 680 M 585 M 674 M 579 M 667 M 500 M 394 M 473 M 552 M 622 M 698 M 744 M 647 M 656 M 656 M 656 M 656 M 299 M 299 M 299 M 435 M 466 M 254 M 271 M 293 M 145 M 165 M 129 M 150 M 167 M 179 M 189 M 98.9 M 104 M 109 M 113 M 112 M 44.8 M 16.2 M 17.4 M 16.8 M 17.6 M 17.6 M 17.6 M 17.6 M -11.3 M -11.3 M -11.3 M -11.3 M -12.8 M -12.8 M -12.8 M -12.8 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Iovance Biotherapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Sutro Biopharma Sutro Biopharma
STRO
$ 8.6 -1.38 % $ 73.1 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 72.94 -6.09 % $ 3.05 B usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
$ 63.39 -2.3 % $ 9.15 B usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 29.91 -4.87 % $ 3.05 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 13.35 -2.73 % $ 1.8 B usaUSA
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
- -6.00 % $ 238 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 16.0 -2.2 % $ 64.2 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
- - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
- 0.38 % $ 12.9 M israelIsrael
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 36.89 -1.78 % $ 2.92 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 16.95 2.02 % $ 2.72 B usaUSA
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
- 2.07 % $ 34.4 M usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 3.01 1.69 % $ 127 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
- -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
- - $ 1.63 B usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
- -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
- 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
- - $ 6.81 B britainBritain
22nd Century Group 22nd Century Group
XXII
$ 0.32 -19.83 % $ 58.9 K usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
$ 926.42 -1.66 % $ 56.8 B niderlandNiderland
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 2.33 -7.25 % $ 19.8 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 21.01 -4.16 % $ 23 B chinaChina
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 1.37 0.74 % $ 98.5 M usaUSA
Zoetis Zoetis
ZTS
$ 78.81 -2.47 % $ 34.9 B usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.47 -4.55 % $ 2.5 M usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA
Zogenix, Inc. Zogenix, Inc.
ZGNX
- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
- -7.58 % $ 264 M usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 3.71 -1.72 % $ 1.19 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 57.41 -1.46 % $ 2.89 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 8.37 -5.64 % $ 1.16 B usaUSA
Veracyte Veracyte
VCYT
$ 25.08 0.16 % $ 1.97 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 24.72 -4.35 % $ 2.79 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 3.44 -6.27 % $ 203 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.16 -12.33 % $ 6.09 M usaUSA